1Jemal, A, Siegel, R, Xu, J, et al. (2010) Cancer statistics, 2010. CA Cancer J Clin 60, 277–300.
3Jemal, A, Murray, T, Ward, E, et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55, 10–30.
4Etzioni, RD, Howlader, N, Shaw, PA, et al. (2005) Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 174, 877–881.
5Saraiya, M, Kottiri, BJ, Leadbetter, S, et al. (2005) Total and percent free prostate-specific antigen levels among U.S. men, 2001–2002. Cancer Epidemiol Biomarkers Prev 14, 2178–2182.
6Catalona, WJ, Partin, AW, Slawin, KM, et al. (2000) Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology 55, 372–376.
7Wallner, LP, Morgenstern, H, McGree, ME, et al. (2011) The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study. Urology 77, 137–141.
8Sonn, GA, Aronson, W & Litwin, MS (2005) Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 8, 304–310.
9Açıkgöz, Ş, Can, M, Doğan, SM, et al. (2011) Prostate specific antigen levels after acute myocardial infarction. Acta Biochim Pol 58, 541–545.
10Grubb, RL 3rd, Black, A, Izmirlian, G, et al. (2009) Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 18, 748–751.
11Singer, EA, Palapattu, GS & van Wijngaarden, E (2008) Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001–2002 National Health and Nutrition Examination Survey. Cancer 113, 2053–2057.
12Krane, LS, Kaul, SA, Stricker, HJ, et al. (2010) Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 183, 118–124.
13Jemal, A, Bray, F, Center, MM, et al. (2011) Global cancer statistics. CA Cancer J Clin 61, 69–90.
14Astorg, P (2004) Dietary n-6 and n-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. Cancer Causes Control 15, 367–386.
15Berquin, IM, Min, Y, Wu, R, et al. (2007) Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 117, 1866–1875.
16Weaver, KL, Ivester, P, Seeds, M, et al. (2009) Effect of dietary fatty acids on inflammatory gene expression in healthy humans. J Biol Chem 284, 15400–15407.
17Simopoulos, AP (2003) Importance of the ratio of omega-6/omega-3 essential fatty acids: evolutionary aspects. World Rev Nutr Diet 92, 1–22.
18Sugano, M & Hirahara, F (2000) Polyunsaturated fatty acids in the food chain in Japan. Am J Clin Nutr 71, 189S–96S.
19Rose, DP & Connolly, JM (1999) Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83, 217–244.
20Connolly, JM, Coleman, M & Rose, DP (1997) Effects of dietary fatty acids on DU145 human prostate cancer cell growth in athymic nude mice. Nutr Cancer 29, 114–119.
21Akinsete, JA, Ion, G, Witte, TR, et al. (2012) Consumption of high ω-3 fatty acid diet suppressed prostate tumorigenesis in C3(1) Tag mice. Carcinogenesis 33, 140–148.
22Kelavkar, UP, Hutzley, J, Dhir, R, et al. (2006) Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. Neoplasia 8, 112–124.
23Kobayashi, N, Barnard, RJ, Henning, SM, et al. (2006) Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res 12, 4662–4670.
24Watts, GF, Playford, DA, Croft, KD, et al. (2002) Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia 45, 420–426.
25Chai, W, Cooney, RV, Franke, AA, et al. (2011) Plasma coenzyme Q10 levels and prostate cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 20, 708–710.
26Hoenjet, KM, Dagnelie, PC, Delaere, KP, et al. (2005) Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study. Eur Urol 47, 433–439.
27Harris, JI, Hibbeln, JR, Mackey, RH, et al. (2004) Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. Prostaglandins Leukot Essent Fatty Acids 71, 263–269.
28Tang, PH, Miles, MV, DeGrauw, A, et al. (2001) HPLC analysis of reduced and oxidized coenzyme Q10 in human plasma. Clin Chem 47, 256–265.
29Loeb, S, Carter, HB, Schaeffer, EM, et al. (2009) Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol 182, 2646–2651.
30Howell, DC (2010) Fundamental Statistics for the Behavioral Sciences. Belmont, CA: Wadsworth Publishing Company.
31Fowke, JH, Signorello, LB, Chang, SS, et al. (2006) Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer 107, 2361–2367.
32Safarinejad, MR, Shafiei, N & Safarinejad, S (2010) Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: a case–control study. Prostate 70, 1645–1657.
33Simopoulos, AP (1999) Essential fatty acids in health and chronic disease. Am J Clin Nutr 70, 3 Suppl., 560S–569S.
34Kolonel, LN (2001) Fat, meat, and prostate cancer. Epidemiol Rev 23, 72–81.
35Augustsson, K, Michaud, DS, Rimm, EB, et al. (2003) A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 12, 64–67.
36Pham, TM, Fujino, Y, Kubo, T, et al. (2009) Fish intake and the risk of fatal prostate cancer: findings from a cohort study in Japan. Public Health Nutr 12, 609–613.
37Terry, P, Lichtenstein, P, Feychting, M, et al. (2001) Fatty fish consumption and risk of prostate cancer. Lancet 357, 1764–1766.
38Allen, NE, Sauvaget, C, Roddam, AW, et al. (2004) A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control 15, 911–920.
39Le Marchand, L, Kolonel, LN, Wilkens, LR, et al. (1994) Animal fat consumption and prostate cancer: a prospective study in Hawaii. Epidemiology 5, 276–282.
40Mills, PK, Beeson, WL, Phillips, RL, et al. (1989) Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64, 598–604.
41Park, SY, Murphy, SP, Wilkens, LR, et al. (2007) Fat and meat intake and prostate cancer risk: the multiethnic cohort study. Int J Cancer 121, 1339–1345.
42Friedrichs, W, Ruparel, SB, Marciniak, RA, et al. (2011) Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression. Nutr Cancer 63, 771–777.
43Giltay, EJ, Geleijnse, JM, Heijboer, AC, et al. (2012) No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. Int J Androl 35, 680–687.
44Reese, AC, Fradet, V & Witte, JS (2009) Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. J Nutrigenet Nutrigenomics 2, 149–158.
45Fradet, V, Cheng, I, Casey, G, et al. (2009) Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res 15, 2559–2566.
46Crane, FL (2001) Biochemical functions of coenzyme Q10. J Am Coll Nutr 20, 591–598.
47Hattersley, JG (1996) Coenzyme Q10 and cancer. J Orthomol Med 2, 111–112.
48Pepping, J (1999) Coenzyme Q10. Am J Health Syst Pharm 56, 519–521.
49Schroder, FH, Dijk, MA, Blom, JM, et al. (2000) Tertiary prevention of prostate cancer by dietary intervention: results of a randomised, double blind, placebo controlled, cross-over study. Eur J Urol 37, 96.
50Folkers, K, Osterborg, A, Nylander, M, et al. (1997) Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 234, 296–299.